Merck strives to commercialize our products in a way that develops our business and meets local needs in a responsible and efficient manner.

Through our worldwide differential pricing framework, Merck is committed to making our medicines and vaccines more affordable to more people by applying a differential pricing approach that takes into account level of economic development, channel and public health need.

For example, in much of the developing world, Merck/MSD offers ROTATEQ^® (Rotavirus Vaccine, Live, Oral, Pentavalent) and GARDASIL^® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] at an access price that is significantly less than the price of these vaccines in developed markets. The access price is exclusive to the public sectors of GAVI-eligible countries, meets the needs of the developing world by facilitating access to these innovative vaccines in the poorest countries, and is affordable and sustainable in the long term.

We invest in activities to increase knowledge among patients and physicians, because we believe that providing support to third-party medical, scientific and patient organizations is an important way to advance our mutual objectives to improve health and to advance patient care. Learn more.

Learn more about pricing of our products here.